CGM for Type 2 Diabetes: What It Is and How It Helps

A continuous glucose monitor, or CGM, is a small wearable sensor that tracks glucose levels around the clock, giving people with type 2 diabetes a near-real-time picture of how food, activity, stress, and medication shape their blood sugar throughout the day. Unlike a traditional finger-stick meter that captures a single snapshot, a CGM records a reading every few minutes and stores it as a continuous trend line. The clinical evidence for this technology in type 2 diabetes has grown substantially in recent years, and it points to meaningful improvements in blood sugar control, fewer dangerous highs and lows, and changes in day-to-day habits that finger-stick testing rarely motivates on its own.

How the Sensor Actually Works

A CGM system consists of a tiny filament inserted just under the skin, usually on the upper arm or abdomen, attached to a small transmitter. The filament sits in the interstitial fluid, the thin layer of liquid that surrounds your cells beneath the skin. It measures glucose in that fluid using an electrochemical reaction on the sensor tip, then wirelessly sends readings to a receiver, smartphone app, or both. Most current sensors last 10 to 14 days before needing replacement.

Because the sensor reads interstitial fluid rather than blood directly, there is a slight delay between what your blood glucose is doing and what the sensor reports. Researchers who directly measured this lag in healthy adults found a transport delay of roughly five to six minutes from the bloodstream to the interstitial space under fasting conditions.¹ In practice, that gap can widen a bit during rapid glucose swings, such as right after eating a high-carb meal or during intense exercise. Several physiological factors can also perturb the relationship between blood and interstitial glucose, including the local tissue response to the sensor itself and wound healing around the insertion site.² This is why manufacturers still recommend confirming a CGM reading with a finger-stick if the number does not match how you feel, especially during fast-changing glucose periods.

What the Clinical Trials Show

The strongest evidence for CGM in type 2 diabetes comes from randomized controlled trials comparing it to standard finger-stick monitoring. A 2024 systematic review and meta-analysis pooling eight trials of people with type 2 diabetes who were not on insulin found that CGM lowered HbA1c by about 0.37 percentage points on average, increased the percentage of time spent in the target glucose range by roughly nine percentage points, and reduced the time spent above range by about eight percentage points.³ Those numbers are across people managing their diabetes with oral medications or lifestyle alone, without any insulin at all.

For people with type 2 diabetes who do use insulin, the improvements tend to be larger. A trial published in JAMA enrolled adults with poorly controlled type 2 diabetes on basal insulin and found that CGM users had a mean HbA1c of 8.0% at eight months compared to 8.4% in the finger-stick group. The CGM group spent 59% of their time in the target range versus 43% for finger-stick users, and their time spent at dangerously high glucose levels (above 250 mg/dL) dropped to 11% compared to 27%.⁴ A 12-month Danish trial of insulin-treated type 2 diabetes found even more pronounced differences, including a between-group HbA1c reduction of 0.9 percentage points, lower daily insulin doses, and weight loss of about 3.3 kilograms in CGM users compared to the finger-stick group.⁵ A separate trial in adults on multiple daily insulin injections reported a more modest but still significant HbA1c advantage of 0.3 percentage points for CGM over six months.⁶

Why Time in Range Matters

HbA1c has been the standard yardstick for diabetes management for decades. It reflects an average blood sugar level over roughly three months. But an average can hide a lot. Two people with the same HbA1c can have very different daily glucose patterns: one might stay relatively stable, while the other swings wildly between highs and lows that cancel each other out. CGM introduced a metric called time in range, which captures the percentage of the day your glucose stays between 70 and 180 mg/dL. This turns out to matter clinically.

A systematic review found that every 10% increase in time in range was associated with reductions in albuminuria (early kidney damage), severity of diabetic retinopathy (eye disease), and prevalence of diabetic nerve damage.⁷ Broader analyses have linked higher time in range to lower risk of cardiovascular death and all-cause mortality as well.⁸ The practical takeaway is that CGM gives you a goal you can act on daily rather than waiting three months to learn your HbA1c. You can see whether a specific meal, a walk after dinner, or a medication change shifted your time in range in real time.

CGM devices also report a value called the glucose management indicator, or GMI, which estimates what your HbA1c would likely be based on your average CGM glucose.⁹ The two numbers do not always match perfectly, because HbA1c reflects biological variation in red blood cell lifespan, but GMI provides a useful ongoing estimate between lab draws.

Glucose Variability and Why Spikes Matter

Beyond the question of average blood sugar, there is growing interest in glucose variability, meaning the size and frequency of the swings between highs and lows. Research in people with type 2 diabetes has linked greater glucose variability to increased oxidative stress, which is a driver of blood vessel damage.¹⁰ In people with recently diagnosed type 2 diabetes and good metabolic control, greater glucose variability was independently associated with markers of cardiovascular damage, including increased heart muscle mass.¹¹

A meta-analysis of CGM trials in type 2 diabetes found that CGM use reduced glycemic variability compared to standard monitoring.¹² A finger-stick meter cannot tell you whether your glucose swung from 250 to 70 and back again between two checks. A CGM can, and that visibility often motivates changes that flatten those swings.

How CGM Changes Behavior

One of the less obvious benefits of CGM is that seeing your glucose rise in real time after specific meals or behaviors creates a feedback loop that finger-stick testing rarely provides. In an early randomized trial, people with poorly controlled type 2 diabetes who used real-time CGM for three-day stretches over three months significantly reduced their daily calorie intake, lost weight, lowered their BMI, and increased their weekly exercise time compared to those using finger-sticks alone.¹³ The HbA1c improvement in the CGM group was 0.7 percentage points greater than in the control group, a difference driven largely by lifestyle changes rather than medication adjustments.

Subsequent work has reinforced this finding. Studies integrating CGM into diabetes education programs have shown improvements in diet, exercise, and self-management behaviors among type 2 diabetes patients on both insulin and non-insulin therapies.¹⁴ The concept extends to earlier stages of the disease as well: researchers have proposed that CGM could guide lifestyle changes in people with prediabetes or early dysglycemia, potentially delaying or preventing progression to full type 2 diabetes.¹⁵

Hypoglycemia and Safety

Hypoglycemia, or dangerously low blood sugar, is a real concern for people on insulin or certain oral medications like sulfonylureas. CGM systems with alarms can alert you when your glucose is dropping toward a dangerous level, sometimes before you feel any symptoms. The same meta-analysis that documented improved time in range also found that CGM reduced time spent below range in type 2 diabetes by a small but meaningful margin.¹² The difference in severe hypoglycemia events between CGM and standard monitoring was not statistically significant in pooled data, but severe hypoglycemia is already rare enough in type 2 diabetes that trials would need much larger numbers to detect a difference.

For healthcare providers, one of the practical values of CGM in type 2 diabetes is identifying hypoglycemia that patients do not know they are having. Professional CGM, where a clinic lends a patient a sensor for one to two weeks and reviews the data at a follow-up visit, can uncover nighttime lows or post-exercise dips that would never show up on an HbA1c report or a handful of finger-sticks.¹⁶

Real-Time CGM Versus Flash Glucose Monitoring

Not all CGM systems work the same way. Real-time CGM (rtCGM) continuously transmits readings and can sound alarms when glucose goes too high or too low. Flash or intermittently scanned CGM (isCGM) stores readings but only shows them when you actively scan the sensor with your phone or reader. The practical difference matters. A head-to-head trial in people with type 1 diabetes found that rtCGM users spent significantly more time in range and less time in hypoglycemia compared to isCGM users, both during exercise and at home.¹⁷ While that trial was in type 1, the alarm function is particularly relevant for anyone on insulin, regardless of diabetes type: if you cannot hear an alert about a dropping glucose, you lose one of the biggest safety advantages of continuous monitoring.

A Lithuanian national survey found that CGM users with continuous alarms reported lower diabetes-related distress, higher confidence in managing hypoglycemia, and lower rates of poor psychological well-being compared to flash monitor users.¹⁸ The peace of mind from knowing you will be warned before a dangerous low hits is hard to quantify, but it shows up consistently in quality-of-life data.

Hospital Visits and Healthcare Costs

Poor glucose control leads to emergency department visits and hospitalizations, and the costs are enormous. A study of Medicaid beneficiaries with type 2 diabetes on multiple daily insulin injections found that after CGM initiation, all-cause hospitalization rates dropped from about 3.25 to 2.29 events per patient-year, and emergency department visits fell from 2.15 to 1.86 events per patient-year. For those on basal insulin therapy alone, hospitalizations and ED visits also decreased significantly.¹⁹ A separate analysis focused on people with type 2 diabetes using intensive insulin therapy reported that the number of individuals with at least one diabetes-related ED visit dropped by 30%, those with inpatient visits dropped by over 40%, and total diabetes-related costs decreased by about $341 per person per month after starting CGM.²⁰

Access, Insurance, and Disparities

Despite the evidence, access to CGM remains uneven. In the United States, Medicare covers CGM for people with diabetes who use insulin and meet certain criteria, but Medicaid coverage varies wildly by state. There is no consistent Medicaid policy for CGM coverage nationwide, and advocacy groups have pushed for standardization across states so that coverage does not depend on geography.²¹ CGM uptake shows persistent disparities by age, race, ethnicity, and insurance type, which limits the population-wide impact of the technology even as the clinical evidence strengthens.²²

The emergence of over-the-counter CGM devices, cleared by the FDA for adults without a prescription, may begin to shift this landscape. These devices are designed for general wellness monitoring rather than clinical diabetes management, but they mark a significant regulatory change that could lower barriers to entry for people who struggle to get a prescription or insurance approval.²³ Whether OTC devices will eventually be suitable for managing diagnosed type 2 diabetes remains an open question.

Skin Reactions and Wearability

Wearing a sensor on your skin continuously for 10 to 14 days can cause problems. The adhesives used to keep CGM sensors in place are documented causes of both allergic and irritant contact dermatitis. The most common allergen is isobornyl acrylate, a chemical found in certain sensor adhesives, though other compounds including epoxy resin and colophonium have also been implicated.²⁴ Estimates of skin reaction prevalence range from roughly 4% to 8% of users.²⁵ Reactions can show up as redness, itching, or blistering at the sensor site, and in some cases as persistent light-colored patches of skin after the sensor is removed.

If you develop a skin reaction, options include rotating sensor sites more aggressively, applying a barrier film or tape underneath the sensor adhesive, or switching to a different brand of CGM whose adhesive uses different chemistry. For people with confirmed allergic contact dermatitis, patch testing by a dermatologist can identify the specific allergen and guide the choice of device.

Data Privacy and Connected Devices

Modern CGM systems generate a continuous stream of detailed health data that syncs to smartphone apps, cloud platforms, and sometimes directly to a healthcare provider’s portal. This creates real privacy questions. Patients have limited ability to control how their glucose data is collected, stored, and used, and existing protections have been described as insufficient to address the risks.²⁶ Data ownership remains legally ambiguous in most places: you, your doctor, the device manufacturer, and the app developer may all have competing claims over the same glucose data.²⁷

Consumer-grade devices and direct-to-consumer health apps often fall outside traditional healthcare data-protection frameworks like HIPAA, which means the protections you might assume apply to your medical data may not cover your CGM data if it flows through a wellness app rather than a clinical system. Before starting CGM, it is worth reading the privacy policy of both the device manufacturer and any associated app, though practically speaking, few people do. The regulatory landscape is still catching up to the technology.

Who Benefits Most and When It May Not Be Necessary

The evidence is strongest for people with type 2 diabetes who use insulin, particularly those with poorly controlled blood sugar. The larger effect sizes in trials of insulin-treated patients make intuitive sense: CGM data helps you adjust doses meal by meal and spot patterns that lead to better insulin timing. For people managing type 2 diabetes with oral medications or lifestyle alone, the benefits are real but more modest, and the value shifts toward behavioral motivation and pattern recognition rather than dose adjustment.

There are situations where CGM may add less value. If your type 2 diabetes is well controlled on a stable medication regimen and your HbA1c is at target, the cost and hassle of a continuous sensor may not be justified unless you want more granular data. Professional CGM, where you wear a sensor for a short diagnostic period rather than continuously, can be a useful middle ground: your care team gets a detailed glucose profile to guide treatment decisions without the ongoing expense of personal CGM.¹⁶ Expanding CGM to broader groups of people with type 2 diabetes, including those not on insulin, could help catch problems early and allow faster medication adjustments, but insurance coverage for that use case remains inconsistent.